Results for this period
First quarter1 March 2026–31 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The company expanded its business scale and improved operational efficiency. The pharmaceutical wholesaling business reported higher revenue and profit, supported by contributions from 3 companies added since May 2025. The dispensing pharmacy business saw a decline in the number of prescriptions due to a decrease in the number of stores, while the healthcare business reported lower profit due to increased labor and personnel costs.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2026–31 May 2026 |
| Net Sales | ¥14,194 million (YoY +5.7%) |
| Operating profit | ¥442 million (YoY +1.8%) |
| Ordinary income | ¥578 million (YoY +17.7%) |
| Profit attributable to owners of the parent | ¥637 million (YoY +45.5%) |
| Net income per share | ¥169.33 |
| Equity ratio | End of the current fiscal period 41.5 / End of previous period 41.7 |
| Total assets | ¥38,158 million |
| Net assets | ¥16,502 million |
| Full-year earnings forecast | Net Sales ¥56,500 million (YoY +2.8%) / Operating profit ¥1,800 million (YoY +0.7%) / Ordinary income ¥1,850 million (YoY -0.5%) / Net income ¥1,300 million (YoY +2.0%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥120 → ¥120（0.0%） |
| Segment revenue | Dispensing Pharmacy Business ¥6,620,953 thousand (YoY +1.2%), Healthcare Business ¥2,328,500 thousand (YoY +7.5%), Pharmaceutical Wholesale Business ¥5,178,707 thousand (YoY +11.2%), Real Estate Business ¥66,813 thousand (YoY +14.1%) |
| Segment profit | Dispensing Pharmacy Business ¥319,367 thousand (YoY -6.2%), Healthcare Business ¥15,092 thousand (YoY -53.4%), Pharmaceutical Wholesale Business ¥107,461 thousand (YoY +34.5%), Real Estate Business ¥40,190 thousand (YoY +24.8%) |
| Depreciation and amortization | ¥182,499 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥129,524 thousand, Gain on sale of investment securities ¥186,400 thousand / Extraordinary loss Loss on sale of fixed assets ¥994 thousand, Loss on Disposal of Fixed Assets ¥2,133 thousand, Loss on sale of investment securities ¥5 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New No / Excluded No / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 3,770,000 Shares |
| Treasury Shares at Period-End | 4,121 Shares |
| Factors Behind Changes in Business Performance | The company expanded its business scale and improved operational efficiency. The pharmaceutical wholesaling business reported higher revenue and profit, supported by contributions from 3 companies added since May 2025. The dispensing pharmacy business saw a decline in the number of prescriptions due to a decrease in the number of stores, while the healthcare business reported lower profit due to increased labor and personnel costs. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company expanded its business scale and improved operational efficiency. In the pharmaceutical wholesaling business, contributions from 3 companies added since May 2025 also contributed to performance. Ordinary profit and net income were additionally supported by recording wage-increase subsidies as non-operating income and a ¥186 million gain on the sale of investment securities. In the dispensing pharmacy business, the number of prescriptions declined due to a decrease in the number of stores, while increased labor and personnel costs reduced profit in the healthcare business.